$0.59
12.25% yesterday
Nasdaq, Apr 07, 09:49 pm CET
ISIN
US76152G1004
Symbol
RVPH
Sector
Industry

Reviva Pharmaceuticals Holdings Inc. Target price 2025 - Analyst rating & recommendation

Reviva Pharmaceuticals Holdings Inc. Classifications & Recommendation:

Buy
100%

Reviva Pharmaceuticals Holdings Inc. Price Target

Target Price $8.80
Price $0.60
Potential
Number of Estimates 5
5 Analysts have issued a price target Reviva Pharmaceuticals Holdings Inc. 2026 . The average Reviva Pharmaceuticals Holdings Inc. target price is $8.80. This is higher than the current stock price. The highest price target is
$16.00 2,566.67%
register free of charge
, the lowest is .
A rating was issued by 5 analysts: 5 Analysts recommend Reviva Pharmaceuticals Holdings Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Reviva Pharmaceuticals Holdings Inc. stock has an average upside potential 2026 of . Most analysts recommend the Reviva Pharmaceuticals Holdings Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.90 -0.66
45.45% 26.67%
P/E negative

2 Analysts have issued a Reviva Pharmaceuticals Holdings Inc. forecast for earnings per share. The average Reviva Pharmaceuticals Holdings Inc. EPS is

$-0.66
Unlock
. This is
26.67% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.44 51.11%
Unlock
, the lowest is
$-0.88 2.22%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.90 45.45%
2025
$-0.66 26.67%
Unlock
2026
$-0.47 28.79%
Unlock
2027
$-0.44 6.38%
Unlock
2028
$0.25 156.82%
Unlock
2029
$0.77 208.00%
Unlock

P/E ratio

Current -0.66 68.87%
2025
-0.91 37.88%
Unlock
2026
-1.29 41.76%
Unlock
2027
-1.38 6.98%
Unlock
2028
2.45 277.54%
Unlock
2029
0.78 68.16%
Unlock

Current Reviva Pharmaceuticals Holdings Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
D. Boral Capital
Locked
Locked
Locked Apr 01 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 22 2025
D. Boral Capital
Locked
Locked
Locked Jan 21 2025
Maxim Group
Locked
Locked
Locked Jan 10 2025
Roth MKM
Locked
Locked
Locked Jan 10 2025
D. Boral Capital
Locked
Locked
Locked Nov 14 2024
D. Boral Capital
Locked
Locked
Locked Nov 13 2024
Analyst Rating Date
Locked
D. Boral Capital:
Locked
Locked
Apr 01 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 22 2025
Locked
D. Boral Capital:
Locked
Locked
Jan 21 2025
Locked
Maxim Group:
Locked
Locked
Jan 10 2025
Locked
Roth MKM:
Locked
Locked
Jan 10 2025
Locked
D. Boral Capital:
Locked
Locked
Nov 14 2024
Locked
D. Boral Capital:
Locked
Locked
Nov 13 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today